Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review

被引:4
|
作者
Shabu, Angel [1 ]
Nishtala, Prasad S. [1 ,2 ,3 ]
机构
[1] Univ Bath, Dept Life Sci, Bath, Somerset, England
[2] Univ Bath, Ctr Therapeut Innovat, Bath, Somerset, England
[3] Univ Bath, Dept Life Sci, Bath BA2 7AY, Somerset, England
关键词
COVID-19; mRNA-1273; moderna; safety; SARS-CoV-2; IMMUNE-SYSTEM; MYOCARDITIS; ANTIBODIES; NATIONWIDE;
D O I
10.1080/14760584.2023.2209177
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Current safety data from Phase 3 clinical trials have concluded that apart from transient local and systemic reactions, no safety concerns were identified for the Moderna COVID-19 vaccine (mRNA-1273). However, Phase 3 studies are insufficient to detect rare adverse events (AEs). A literature search of the two major electronic databases, Embase and PubMed, was performed to enable the identification and characterization of all relevant articles from December 2020 to November 2022. Areas Covered This narrative review summarizes the key safety outcomes associated with the mRNA-1273 vaccine to inform healthcare decisions and increase public awareness of mRNA-1273 vaccine safety. The primary adverse events (AEs) reported within a diverse population, receiving the mRNA-1273 vaccine, were; localized injection site pain, fatigue, headache, myalgia, and chills. In addition, the mRNA-1273 vaccine was also associated with; less than a 1-day change in the menstrual cycle, a 10-fold higher risk of myocarditis and pericarditis within young males aged 18-29 years and increased levels of anti-polyethylene glycol (PEG) antibodies. Expert Opinion The transient nature of commonly observed AEs and the rare occurrence of severe events within mRNA-1273 recipients show no significant safety concerns which should prevent vaccination. However, large-scale epidemiological studies with longer follow-up periods are required to surveillance rare safety outcomes.
引用
收藏
页码:393 / 409
页数:17
相关论文
共 50 条
  • [1] Moderna mRNA-1273 vaccine against Covid-19: decision support
    不详
    [J]. EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2021, (175): : 320 - 321
  • [2] Erythema nodosum after Moderna mRNA-1273 COVID-19 vaccine
    Teymour, Shereen
    Ahram, Aya
    Blackwell, Tim
    Bhate, Chinmoy
    Cohen, Philip J.
    Whitworth, Jeffrey M.
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (04)
  • [3] Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine
    Malayala, Srikrishna, V
    Mohan, Gisha
    Vasireddy, Deepa
    Atluri, Paavani
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (03)
  • [4] Moderna's Covid-19 mRNA 1273 vaccine
    不详
    [J]. EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2021, (175): : 322 - 323
  • [5] Bell's palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19
    Poudel, Sujan
    Nepali, Prakash
    Baniya, Santosh
    Shah, Sangam
    Bogati, Sunil
    Nepal, Gaurav
    Ojha, Rajeev
    Edaki, Omoyeme
    Lazovic, Gavrilo
    Kara, Sam
    [J]. ANNALS OF MEDICINE AND SURGERY, 2022, 78
  • [6] Breakthrough COVID-19 Infection in Hemodialysis Patients Following mRNA-1273 (Moderna) Vaccine Administration
    Fuca, Nicholas
    Chan, Lili
    Campbell, Kirk N.
    Shaikh, Aisha
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 98 - 98
  • [7] Acquired Angioedema Acute Attack After Administration of the Moderna COVID-19 (mRNA-1273) Vaccine
    Graziani, Alessandro
    Savrie, Caterina
    Sama, Maria Giulia
    [J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59 (03): : 165 - 166
  • [8] Cutaneous arteritis following mRNA-1273 Moderna COVID-19 vaccination
    Ogawa, T.
    Aitake, U.
    Nomura, T.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (06) : E399 - E400
  • [9] Delayed Skin Reactions to COVID-19 mRNA-1273 Vaccine: Case Report and Literature Review
    Wang, Ruei-Lin
    Chiang, Wen-Fang
    Chiu, Chih-Chiun
    Wu, Kuo-An
    Lin, Chia-Yi
    Kao, Yung-Hsi
    Chuu, Chih-Pin
    Chan, Jenq-Shyong
    Hsiao, Po-Jen
    [J]. VACCINES, 2022, 10 (09)
  • [10] Lymphohistiocytic Myocarditis and Moderna mRNA-1273 Vaccine
    Sookaromdee, Pathum
    Wiwanitkit, Viroj
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2022, 158 (02) : 311 - 311